Assessment of Immune Response in Multiple Sclerosis Patients With COVID-19/Vaccination Treated With Ofatumumab and Other Disease Modifying Therapies

NCT05950308 · clinicaltrials.gov ↗
COMPLETED
Status
61
Enrollment
INDUSTRY
Sponsor class

Conditions

Sponsor

Novartis Pharmaceuticals